Dynamin Inhibitory Peptide Mechanisms, Clinical Applications

Dynamin Inhibitory Peptide: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Dynamin inhibitory peptide (DIP) is a synthetic peptide designed to selectively inhibit the GTPase activity of dynamin, a large GTPase implicated in the scission of clathrin-coated vesicles during endocytosis. Dynamin plays a pivotal role in membrane remodeling events, including synaptic vesicle recycling, receptor-mediated endocytosis, and organelle division (Ferguson & De Camilli, 2012, Nat Rev Mol Cell Biol). By mimicking the proline-rich domain (PRD) of dynamin’s binding partners, DIP competitively disrupts the interaction between dynamin and SH3 domain-containing proteins, thereby inhibiting dynamin’s function (Grabs et al., 1997, Nature). This targeted inhibition has rendered DIP a valuable tool in dissecting endocytic pathways and exploring therapeutic avenues in diseases characterized by aberrant endocytosis.

The mechanism of action of DIP centers on its ability to bind the SH3 domain of amphiphysin and other endocytic accessory proteins, preventing their recruitment to dynamin and thus blocking vesicle fission (Shupliakov et al., 1997, Cell). This mechanistic specificity distinguishes DIP from small-molecule dynamin inhibitors, which may have broader off-target effects. The peptide’s utility extends from basic research in cell biology to potential clinical applications in oncology, neurology, and infectious diseases.

Clinical Value and Applications
DIP’s primary clinical value lies in its capacity to modulate endocytosis, a process exploited by various pathogens and implicated in cancer cell survival and drug resistance. In oncology, tumor cells often upregulate endocytic pathways to internalize growth factors and evade immune surveillance (Mellman & Yarden, 2013, Nat Rev Cancer). By inhibiting dynamin-dependent endocytosis, DIP can reduce receptor internalization and downstream signaling, potentially sensitizing cancer cells to chemotherapeutic agents.

In the context of neurodegenerative diseases, excessive or dysregulated synaptic vesicle recycling has been linked to synaptic dysfunction and neuronal loss (Clayton & Cousin, 2009, Nat Rev Neurosci). DIP has been employed in experimental models to transiently inhibit synaptic vesicle endocytosis, providing insights into the pathophysiology of disorders such as Alzheimer’s disease and Parkinson’s disease.

Moreover, many viruses, including influenza and hepatitis C, utilize clathrin-mediated endocytosis for cellular entry (Mercer et al., 2010, Annu Rev Biochem). DIP has demonstrated efficacy in blocking viral entry in vitro, suggesting a potential role as an antiviral agent or as a research tool for studying viral infection mechanisms.

[Related: clozapine n-oxide] Key Challenges and Pain Points Addressed
Current pharmacological inhibitors of dynamin, such as dynasore and its analogs, often suffer from limited specificity and off-target effects, complicating data interpretation and limiting translational potential (McCluskey et al., 2013, J Biol Chem). DIP addresses these challenges by providing a more selective approach, targeting protein-protein interactions essential for dynamin function rather than its catalytic site. This specificity reduces the likelihood of interfering with other GTPases or unrelated cellular processes.

Another pain point in endocytosis research is the transient and reversible nature of many small-molecule inhibitors. DIP, as a peptide, can be engineered for enhanced stability and cell permeability, allowing for more sustained inhibition in cellular and animal models. Furthermore, DIP’s modular design enables the incorporation of cell-penetrating sequences or chemical modifications to improve pharmacokinetics and tissue targeting.

In clinical research, DIP offers a means to dissect the contribution of dynamin-dependent endocytosis to disease progression without the genetic manipulation required for knockout models. This is particularly valuable in primary human cells or in vivo systems where genetic approaches are impractical.

Literature Review
Several key studies have elucidated the role of dynamin inhibitory peptides in cellular and disease models:

1. Grabs et al. (1997, Nature) first demonstrated that peptides derived from the PRD of dynamin-binding proteins could inhibit dynamin function by blocking SH3 domain interactions, leading to impaired endocytosis in neuronal cells.

2. Shupliakov et al. (1997, Cell) used a dynamin inhibitory peptide to acutely block synaptic vesicle recycling in lamprey neurons, revealing the essential role of dynamin in synaptic transmission.

3. Damke et al. (2001, J Cell Biol) reported that dynamin inhibition by peptides or dominant-negative mutants disrupted clathrin-mediated endocytosis, affecting receptor internalization and downstream signaling.

4. Henley et al. (1999, J Neurosci) utilized DIP to investigate the role of endocytosis in synaptic plasticity, showing that transient inhibition of dynamin impaired long-term potentiation in hippocampal slices.

5. Preta et al. (2015, Front Pharmacol) reviewed the application of dynamin inhibitors, including peptides, in cancer research, highlighting their potential to block nutrient uptake and sensitize tumor cells to apoptosis.

6. Roux et al. (2005, J Biol Chem) demonstrated that DIP could inhibit the entry of hepatitis C virus in hepatocytes, underscoring its antiviral potential.

7. McCluskey et al. (2013, J Biol Chem) compared the specificity of peptide-based and small-molecule dynamin inhibitors, concluding that DIP offered superior selectivity with fewer off-target effects.

[Related: a 83] Experimental Data and Results
Experimental studies employing DIP have consistently shown effective inhibition of dynamin-dependent endocytosis. In neuronal cultures, application of DIP at micromolar concentrations resulted in a rapid cessation of synaptic vesicle recycling, as evidenced by the accumulation of endocytic intermediates and reduced neurotransmitter release (Shupliakov et al., 1997, Cell). Electrophysiological recordings confirmed a decrease in synaptic transmission, which was reversible upon peptide washout.

In cancer cell lines, DIP treatment led to a significant reduction in the internalization of transferrin and epidermal growth factor receptors, as measured by flow cytometry and confocal microscopy (Preta et al., 2015, Front Pharmacol). This inhibition correlated with decreased cell proliferation and increased sensitivity to chemotherapeutic agents, suggesting a synergistic effect.

Antiviral studies have shown that pre-treatment of hepatocyte cultures with DIP reduced hepatitis C virus entry by over 70%, as quantified by viral RNA levels and immunofluorescence assays (Roux et al., 2005, J Biol Chem). Importantly, cell viability assays indicated minimal cytotoxicity at effective concentrations, supporting the peptide’s safety profile in vitro.

Comparative studies with small-molecule inhibitors revealed that DIP exhibited greater selectivity for dynamin-mediated processes, with negligible effects on unrelated GTPases or cytoskeletal dynamics (McCluskey et al., 2013, J Biol Chem). This specificity was attributed to the peptide’s targeted disruption of SH3 domain interactions, as confirmed by co-immunoprecipitation and pull-down assays.

Usage Guidelines and Best Practices
For optimal results, DIP should be reconstituted in sterile water or appropriate buffer to a stock concentration of 1–10 mM and stored at –20°C. Working concentrations typically range from 10 to 100 μM, depending on cell type and experimental objectives. It is recommended to include appropriate controls, such as scrambled peptide sequences or vehicle-only treatments, to account for non-specific effects.

Cellular uptake of DIP can be enhanced by conjugation to cell-penetrating peptides (e.g., TAT or penetratin) or by using lipid-based delivery systems. For in vivo applications, peptide stability can be improved through N-terminal acetylation, C-terminal amidation, or incorporation of D-amino acids.

Time-course experiments are advised to determine the onset and reversibility of inhibition, as well as to monitor potential compensatory mechanisms. It is also essential to assess cell viability and off-target effects using standard assays (e.g., MTT, LDH release, or flow cytometry).

Given the peptide’s mechanism of action, researchers should be aware that DIP may affect multiple endocytic pathways beyond clathrin-mediated endocytosis, including caveolar and non-clathrin-mediated routes. Thus, pathway-specific markers and assays should be employed to delineate the scope of inhibition.

[Related: rsl3 gpx4 inhibitor] Future Research Directions
Despite its utility, several challenges remain in translating DIP from bench to bedside. Future research should focus on improving the pharmacokinetic properties of DIP, including serum stability, tissue penetration, and targeted delivery. The development of peptide analogs with enhanced selectivity for specific dynamin isoforms (e.g., dynamin-1 in neurons versus dynamin-2 in non-neuronal tissues) could enable more precise modulation of endocytic processes in different disease contexts.

Further studies are warranted to evaluate the long-term effects of dynamin inhibition in animal models, particularly with respect to neuronal function, Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 65 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11457296